ABC | Volume 114, Nº6, Junho 2020

Ponto de Vista Wu et al. Prevenção de Torsades de Pointes no tratamento com hidroxicloroquina/ azitromicina Arq Bras Cardiol. 2020; 114(6):1061-1066 TC, Sacilotto L, Darrieux FCC, Pisani CF, Melo SL, Hachul DT, Scanavacca M. Potencial conflito de interesses Os autores declaram não haver conflito de interesses pertinentes. Fontes de financiamento O presente estudo não contou com fontes de financiamento externas. Vinculação acadêmica Não há vinculação deste estudo a programas de pós- graduação. Aprovação ética e consentimento informado Este artigo não contém estudos com humanos ou animais realizados por nenhum dos autores. Tabela 3 – Manejo Farmacológico da arritmia ventricular e/ou TdP Lidocaína Dose de ataque – 1,0 a 1,5mg/kg IV com doses repetidas em bolus de 0,5- 0,75 mg/kg em bolus até 3 mg/kg. Manutenção – 20 mcg/kg/min IV. Sulfato de magnésio 2 a 4 g IV Isoprotenerol Dose de ataque: 1 a 2 mcg IV. Manutenção; 0,15 mcg/min e titular até 0,3 mcg/min de acordo com a resposta ou necessidade clínica. 1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 02;382(8):727-33. 2. worldometers. https://www.worldometers.info/coronavirus/ [Cited in 2020, April 03] Available from: https://www.worldometers.info/ coronavirus/. 3. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 03;30(3):269-71. 4. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug;2:69. 5. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-9. 6. U.S. Food and Drug Administration. (FDA) Coronavirus Disease 2019 (COVID - 19) [Cited in 2020 March 28]. Available from: https://www.fda. gov/news-events/press-announcements/coronavirus-covid-19-update- daily-roundup-march-30-2020. 7. Agência Nacional de Vigilância Sanitária. Anvisa. Covid-19: liberada pesquisa com hidroxicloroquina. [Citado em 27 março 2020] Disponível em :http://portal.anvisa.gov.br/ 8. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar:105949. 9. Bacharier LB, Guilbert TW, Mauger DT, Boehmer S, Beigelman A, Fitzpatrick AM, et al. Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Clinical Trial. JAMA. 2015 Nov;314(19):2034-44. 10. Guo D, Cai Y, Chai D, Liang B, Bai N, Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010 Sep;65(9):631-40. 11. Chen CY, Wang FL, Lin CC. Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia. Clin Toxicol (Phila). 2006;44(2):173-5. 12. TisdaleJE,JaynesHA,KingeryJR,MouradNA,TrujilloTN,OverholserBR,etal. Development and validation of a risk score to predict QT interval prolongation inhospitalizedpatients.CircCardi.ovascQualOutcomes.2013Jul;6(4):479-87. 13. GiudicessiJR,NoseworthyPA,FriedmanPA,AckermanMJ.UrgentGuidancefor NavigatingandCircumventingtheQTcProlongingandTorsadogenicpotential ofpossiblepharmacotherapiesfor(COVID-19). MayoClinProc.xxx2020:1-9. [In Press] 14. Malviya A. Ventricular Arrhythmia Risk Due to Hydroxychloroquine- Azithromycin Treatment For COVID-19. Indian Heart J. 2020 Apr 27 [Epub ahead of print] 15. Priori SG, Schwartz PJ, Napolitano C, Bloise R, Ronchetti E, Grillo M, et al. Risk stratification in the long-QT syndrome. N Engl J Med. 2003 May;348(19):1866-74. 16. Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med. 2009 Sep;43(9):657-62. 17. PostemaPG,WildeAA.ThemeasurementoftheQTinterval.CurrCardiolRev. 2014 Aug;10(3):287-94. 18. El-Sherif N, Turitto G, Boutjdir M. Acquired Long QT Syndrome and Electrophysiology of Torsade de Pointes. Arrhythm Electrophysiol Rev. 2019;8(2):122-30. 19. CredibleMeds.QuicksearchfordrugsontheQTdrugs lists- [Cited in2020Apr 20]. [Available from: crediblemeds.org. 20. Panchal AR, Berg KM, Kudenchuk PJ, Del Rios M, Hirsch KG, Link MS, et al. 2018AmericanHeartAssociationFocusedUpdateonAdvancedCardiovascular Life Support Use of Antiarrhythmic Drugs During and Immediately After Cardiac Arrest: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2018 12;138(23):e740-e9. 21. SorajjaD,MungerTM,ShenWin-KuangS.Optimalantiarrhythmicdrugtherapy for electrical storm. J Biomed Res. 2015;29(1):20-34. Referências Este é um artigo de acesso aberto distribuído sob os termos da licença de atribuição pelo Creative Commons Contribuição dos autores Concepção e desenho da pesquisa e Obtenção de dados: Wu TC; Redação do manuscrito: Wu TC, Sacilotto L, Darrieux FCC, Pisani CF, Hachul DT; Revisão crítica do manuscrito quanto ao conteúdo intelectual importante: Wu 1066